Vatuximab(Trademark): Optimizing Therapeutic Strategies for Prostate Cancer Based on Dynamic MR Tumor Oximetry

摘要

We investigated a novel therapy for prostate cancer using bavituximab, which targets phosphatidylserine expressed on tumor vasculature. Normally, phosphatidylserine exclusively resides on the cytosolic leaflet of the plasma membrane, however, in tumors phosphatidylserine becomes externalized providing a target. It was reported that bavituximab not only targets various tumors, but also induces vascular damage and tumor regression with minimal accompanying toxicity. We found that bavituximab caused little acute pathophysiological response in prostate tumors. Its effect is more subtle than classic vascular disrupting agents. However, in combination with docetaxel there was significantly enhanced tumor growth delay, notably in an intra osseous model of metastatic prostate cancer. Bavituximab is being developed by Peregrine Pharmaceuticals for clinical trials.